Eli Lilly has posted a 58.1% one-year return on the strength of its GLP-1 weight-loss and diabetes franchise (Zepbound, Mounjaro), and its A+ profitability grade is the best in this entire batch. It's arguably the most growth-oriented name in the healthcare sector here.

That growth is already substantially priced in through a D valuation grade (~39x P/E), so pipeline trial results or competitive progress from rivals like Novo Nordisk can swing the stock meaningfully. Treat it as a healthcare growth name, but factor in the concentration risk of relying heavily on a single drug franchise.